New Insulin’s: Benefits and Challenges

\r\n Insulin degludec seemed to demonstrate a reduction in episodes of hypoglycemia, especially nocturnal hypoglycemia, by approximately 25% compared with insulin glargine, the FDA in its assessment highlighted the fact that this benefit was not a consistent feature seen across the different types of diabetes or definitions of hypoglycemia, in particular the more objective definitions of hypoglycemia .B enefits include flexibility of timing of insulin administration, the lack of weight gain or even weight loss, and some improvement in quality-of-life aspects.

\r\n

    Related Conference of New Insulin’s: Benefits and Challenges

    New Insulin’s: Benefits and Challenges Conference Speakers